Trials Sponsors Conditions Drugs Pricing

Conditions

Type2 Diabetes Heart Failure

Outcome Measures

Primary Outcomes (2)

Change to be observed with canagliflozin on myocardial dietary fatty acid uptake
will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA) with sequential dynamic. PET/CT scanning.
3 months
Change to be observed with canagliflozin on whole-body partitioning.
will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA, with static PET/CT scanning
3 months

Secondary Outcomes (3)

myocardial and liver NEFA uptake
3 months
NEFA oxidative rate
3 months
plasma NEFA turnover
1 year

Other Outcomes (6)

Insulin sensitivity
1 year
Insulin secretion rate
1 year
β-cell function
1 year
+3 more other outcomes

Study Arms (2)

Treatment 1

PLACEBO COMPARATOR

placebo oral capsule will be administered once daily, for 2 weeks

Drug: Placebo oral capsuleRadiation: PET imaging

Treatment 2

EXPERIMENTAL

Canagliflozine 100mg once daily, for 2 weeks

Drug: Canagliflozin 100mgRadiation: PET imaging

Interventions

Canagliflozin 100mgDrug

2-week intervention

Also known as: Invokana

Treatment 2

Placebo oral capsuleDrug

2-week intervention

Treatment 1

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

HbA1c 7.5 -10.5%;
LVEF \< 40%;

Sponsors & Collaborators

Janssen Inc.
Industrycollaborator
Université de Sherbrooke
Otherlead

MeSH Terms

Conditions

Heart Failure

Interventions

CanagliflozinMagnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ThiophenesSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 1-RingHeterocyclic CompoundsGlucosidesGlycosides

Study Officials

André C. Carpentier
Université de Sherbrooke
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
Purpose: BASIC SCIENCE
Intervention Model: CROSSOVER
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: tenured professor

Study Record Dates

First Submitted

September 26, 2017

First Posted

September 29, 2017

Study Start

May 1, 2018

Study Stopped

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Other Outcomes (6)

Study Arms (2)

Treatment 1

Treatment 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Other Outcomes (6)

Study Arms (2)

Treatment 1

Treatment 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record